ArticleThe journal of headache and pain2025
Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study.
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
China Headache and Vertigo Registry Study
A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study
Who cites it
4 citing papers in PubMed.
- Rimegepant for vestibular and cochlear symptoms associated with vertigo in a real-world retrospective study.iScience · 2026Article
- CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?European journal of neurology · 2026Review
- Migraine and auditory dysfunction: beyond comorbidity.Journal of neurology · 2026Review
- Current Practices in Vestibular Migraine Management Among Canadian Otolaryngologists: A National Survey.Audiology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundVestibular migraine (VM) is the second most common cause of episodic vertigo worldwide, yet effective therapeutic options remain limited. This study aimed to assess the clinical effectiveness of rimegepant in patients with VM.
methodsA total of 33 VM cases were enrolled in this multicenter, prospective self-controlled cohort study, screened from an initial pool of 106 patients. Participants were orally administered rimegepant at 75 mg every other day as a preventive therapy. Mean 4-week days of vestibular symptom or headache, along with Dizziness Handicap Inventory (DHI), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Headache Impact Test-6 (HIT-6), Vertigo Symptom Scale–Short Form (VSS-SF), Activities-specific Balance Confidence Scale (ABC) scores, and hearing sensitivities were compared between pre-dosing and postdosing of rimegepant over a 4-week follow-up.
resultsAt baseline, participants exhibited a high symptom burden, with elevated DHI, VSS-SF, GAD-7, PHQ-9, and HIT-6 scores and low ABC scores. After rimegepant treatment, there were substantial reductions in monthly vestibular symptom days and headache days (differences: vestibular symptoms, -8.48; headache, -5.88). Totally 63.6% and 70.4% of the patients experienced a 50% reduction in vestibular symptom days and headache days, respectively. Notably, these improvements were already apparent at 2 weeks, indicating early onset of efficacy. Additionally, rimegepant treatment led to significant improvements in vestibular function (differences: DHI, -27.33; VSS-SF, -6.21), psychological status (differences: GAD-7, -3.33; PHQ-9, -3.33), and quality of life (differences: HIT-6, -11.27; ABC, 19.98). In the 22 participants who underwent baseline and 4-week hearing assessments, pure tone audiometry (PTA) results also indicated improvements in hearing.
conclusionsRimegepant provides relief of vestibular symptoms and improves psychological well-being and hearing in patients with VM, with efficacy evident as early as 2 weeks.
trial registrationNCT04939922.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.